Neuphoria falls, scraps social anxiety program after drug trial failure

Neuphoria Therapeutics

21/10/2025 10:20

** Shares of drug developer Neuphoria Therapeutics NEUP.O fall 65% to $1.89 premarket

** NEUP to discontinue development of its social anxiety disorder program after BNC210 fails in late-stage AFFIRM-1 trial

** Co says late-stage trial of its experimental drug BNC210 in social anxiety disorder failed to meet main or secondary goals

** BNC210 is an experimental anti-anxiety drug designed to reduce stress without sedation or addiction - NEUP

** Co has Alzheimer's drug partnership with Merck MRK.N; eligible for up to $450 mln in milestones

** Up to last close, stock up ~349% YTD

 (Compiled by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))